PROMETRIKA
A FULL-SERVICE CRO

NEWSLETTER

CEO Corner

MIGANUSH STEPANIANS, PH.D.

Welcome to PROMETRIKA's 2020 mid-year newsletter! The first half of 2020 has indeed been a remarkable time for all of us. The Global COVID-19 pandemic has impacted communities and individuals worldwide and continues to be a major factor in our personal and professional lives. Since mid-March, the PROMETRIKA team has worked 100% remotely and our leadership team has been focused on ensuring completely seamless continuity of operations and delivery of services with the excellence that you have come to expect from us. Our robust computer systems managed by our highly expert technology team have enabled the efficient delivery of clinical trial services to our clients. In collaboration with our sponsors, we have successfully replaced on-site monitoring activities with comprehensive remote monitoring. We are proud to have been able to contribute to the tireless efforts of our industry in the search for therapeutics to combat this daunting pandemic. We have recently initiated a fully remote clinical trial for a therapeutic agent for treatment of COVID-19. This is one of the several opportunities afforded to us by our clients to conduct, manage, and analyze data for clinical trials of treatments for COVID-19. Our clients have also leveraged our expertise to shape, re-evaluate, and modify their strategies for dealing with the impact of this pandemic on their ongoing clinical trials.

We continue to provide ideas and solutions to our sponsors to mitigate the impact on the conduct, data management, and analysis of current trials. In the meantime, all of our departments have added new team members in the past 6 months and our list of clients now exceeds 130. Late in 2019, our leadership team was greatly enhanced when we were joined by Kirsten Flaherty as our new Head of Human Resources. A leader in human resources strategy, talent development and operations, Kirsten has held leadership positions in Human Resources at several local companies, most recently, at Foundation Medicine. I am so pleased to have such a strong HR leader in our company, especially during these unprecedented times.

Kind regards,



Research on Lysosomal Disease

PROMETRIKA's **Chris Gallant**, **Chelsey Ryan** and **Heather Paden** attended the 16th Annual WORLDSymposium on February 10–13, 2020 in Orlando, FL.

The symposium hosts basic, translational, and clinical researchers, patient advocacy groups, and clinicians interested in learning more about the latest discoveries and clinical investigations related to lysosomal diseases. The emerging trends this year focused on mechanism of action, dosing regimens, small molecules and gene therapies. The symposium also included a discussion of earlier treatment to improve long-term outcomes, and how to engage patients in clinical research by including prioritization of symptoms when designing study endpoints.

Valued Partner in the Fight against COVID-19

PROMETRIKA is collaborating with **Karyopharm Therapeutics** to conduct the first randomized clinical trial for low-dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19. Karyopharm and PROMETRIKA are working closely with investigators and hospital sites at unprecedented speed to accurately capture the data needed to fast-track early findings. The goal is to add to the growing body of evidence that XPO1 inhibitors may play an important role in treating people with this life-threatening viral infection.

Karyopharm Therapeutics

MassBio Data Certainty in Times of COVID-19 and Beyond

Chelsey Ryan, Sr. Clinical Trial Manager, joined a MassBio panel discussing the importance in today's world for clinical trial sponsors to embrace technical innovation. The virtual forum on June 4th focused on how tools such as eSource and Direct Data Capture help trialists make confident, informed decisions, ensuring certainty of data from initial collection to regulatory submission.

Clinical Data Experts "Meet" in Berlin

In April, PROMETRIKA's **Susan Boquist,** Assoc. Dir., Statistical Programming, attended the Clinical Data Interchange Standards Consortium (CDISC) European Interchange, presented virtually from Berlin, Germany. First unveiled at the conference, the CDISC COVID-19 interim user guide provides examples and guidance on implementing CDISC standards for COVID-19 so that researchers can collect, structure, and analyze data more effectively to amplify the full value of data, drive clinical research forward, and improve global health.

Participants at the conference learned that LOINC coding, which allows for clearer classification of laboratory values, is being integrated into FDA requirements. Talks covered the use of EHR data to reduce time and cost, and the use of real world data in place of placebo testing, to save effort and address potential ethical concerns. Submission preparation covered structuring programs, ensuring data traceability, and documenting analysis conduct. The conference ended with discussions by representatives from the Heads of Medicines Agencies/European Medicines Agency (HMA/EMA), Pharmaceuticals and Medical Devices Agency (PMDA), and US FDA, who gave excellent talks and took the time to answer questions posed by the international audience.

Creating Harmonious SDTM Domains

Last October, **Susan Boquist**, Associate Dir., Statistical Programming, traveled to CDISC International Interchange in San Diego, CA to present the poster, "Creating Harmonious SDTM Domains".

The poster was created in collaboration with Principal Statistical Programmers:
Elena Prosekova,
Natalia Quinn
and
Sofia Tyryshkina.



Mapping raw data into standardized, tabulated data sets can be a daunting task to undertake, especially if one has not done it before. Even seasoned mappers could use the help of some additional ideas and tips. The poster shared the authors' thoughts, suggestions and examples to help turn a cacophony of raw data into a standardized symphony that will flow into analysis.

The poster was well received and Susan handed out a number of postcard sized replicas for interested attendees. A second opportunity to present the poster, along with a paper at PharmaSUG in San Francisco, CA in May 2020, did not materialize when the conference was cancelled due to the pandemic. The authors will try again next year.

Real World Evidence (RWE)

For a concentrated look on the topic of Real-World Evidenc (RWE), **Sofia Tyryshkina**, Principal Statistical Programmer at PROMETRIKA, attended PHUSE's virtual one day event titled "RWE: A New Gold Rush Revolutionizing Data Collection, Analysis and Submission".

With digitization of healthcare and explicit regulatory and legislative support from the FDA, RWE is ushering a new era of data insights with the potential to significantly reduce the entire product development life cycle. Will RWE insights ever replace the need for randomized clinical trials? Will investing in RWE analytical capabilities accelerate the bench-to-bedside process and bring better drugs to market faster?

This informative event gave us a better understanding of RWE, the slowly changing data landscape, and a new perspective on data insights to further enhance the health care system and patient outcomes.

PUBLICATIONS

Congratulations to PROMETRIKA's **Dr. Heidy Russell**, Director of Biostatistics, who is a co-author of a publication in Diabetes, Obesity and Metabolism, entitled "A 12-week randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes." Bexagliflozin confers substantial and dose-dependent benefits on subjects with type 2 diabetes and has an acceptable safety profile.
https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13928

Dr. Soudeh Ansari published in the American Society of Reproductive Medicine's Fertility and Sterility journal the article entitled, "Infertility patient clinical journey outcome depends on initial treatment, starting with ovulation induction (OI) vs in vitro fertilization (IVF): results from a large real-world database."
https://www.fertstert.org/article/S0015-0282(19)31735-2/fulltext

Congratulations to Acceleron and Epizyme!

Epizyme received U.S. FDA accelerated approval of **TAZVERIK™ (tazemetostat)** for the treatment of patients with epithelioid sarcoma. A second NDA for TAZVERIK for the treatment of follicular lymphoma is pending. TAZVERIK is the first and only EZH2 inhibitor approved by the FDA.

Acceleron received FDA approval of **Reblozyl® (luspatercept-aamt)**, the first and only erythroid maturation agent, to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS). This approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with MDS who require red blood cell (RBC) transfusions and have failed an erythropoiesis stimulating agent.